Proactive Investors - Run By Investors For Investors

Futura Medical pushing ahead with further CSD500 condom launches

James Barder, chief executive of Futura Medical plc. (LON:FUM) tells Proactive's Andrew Scott they've had a very productive six months as their breakthrough erectile dysfunction gel moves closer to its phase III study.

A mid-stage trial last September showed that MED2002 gets to work quicker than its competitors and has a favourable safety profile.

Futura also has its CSD500 erectogenic condom which was launched in Saudi Arabia at the beginning of the year.

They were dealt a blow by one its licensing partners, Church & Dwight Co Inc (NYSE:CHD), in August after it terminated its licensing agreement for CSD500 following a strange of strategy.

 
Meet W Resources PLC, Avation PLC, Anglo Asian Mining PLC and Salt Lake Potash Ltd at our event, London , 28 February 2019. Register here »
View full FUM profile View Profile

Futura Medical PLC Timeline

Newswire
December 17 2018

© Proactive Investors 2019

Proactive Investors Limited, trading as “Proactiveinvestors United Kingdom”, is Authorised and regulated by the Financial Conduct Authority.
Registered in England with Company Registration number 05639690. Group VAT registration number 872070825 FCA Registration number 559082. You can contact us here.

Market Indices, Commodities and Regulatory News Headlines copyright © Morningstar. Data delayed 15 minutes unless otherwise indicated. Terms of use